Drugs / 68Ga-MAA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04942275 | Jul 2021 → Jul 2022 | non-small cell lung carcinoma | University Hospital, Brest | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-MAA | “The radiopharmaceutical used for lung perfusion PET consists in human albumin macroaggregates labeled with Ga-68 (68Ga-MAA).” NCT04942275 ↗ |
| Modality | Diagnostic / imaging agent | “The radiopharmaceutical used for lung perfusion PET” NCT04942275 ↗ |
| Route | Intravenous | “68Ga- MAA are administrated intravenously.” NCT04942275 ↗ |